Actinogen Medical Advances Alzheimer’s and Depression Treatment with Xanamem

The latest update is out from Actinogen Medical Limited ( (AU:ACW) ).

Actinogen Medical announced that its CEO, Dr. Steven Gourlay, will present at the ASX small & mid-caps conference, discussing their novel drug Xanamem, which targets brain cortisol to slow Alzheimer’s progression and treat depression. The company is advancing its pivotal Phase 2b/3 trial for Alzheimer’s and has shown promising results in a Phase 2a trial for depression, highlighting Xanamem’s potential impact on the treatment landscape for these conditions.

More about Actinogen Medical Limited

Actinogen Medical is an ASX-listed biotechnology company focused on developing novel therapies for neurological and neuropsychiatric diseases linked to dysregulated brain cortisol. Their lead compound, Xanamem, is being developed as a treatment for Alzheimer’s Disease and Depression, with potential future applications in Fragile X Syndrome and other conditions. The company aims to address the substantial unmet medical need for improved treatments for cognitive dysfunction and behavioral abnormalities associated with these diseases.

YTD Price Performance: 25.00%

Average Trading Volume: 75,000

Technical Sentiment Signal: Sell

Current Market Cap: $66.98M

Learn more about ACW stock on TipRanks’ Stock Analysis page.